Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00304096 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Treating Patients With Stage III or Stage IV Breast Cancer
A Phase 1 study, sponsored by University of Virginia.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00304096 is a Phase 1 study that has completed, run by University of Virginia. The registered enrollment target is 12 participants.
The verdict
NCT00304096, a Phase 1 study, has completed, sponsored by University of Virginia.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Giving booster vaccinations may make a stronger immune response and kill more tumor cells. PURPOSE: This phase I trial is studying the side effects of vaccine therapy in treating patients with stage III or stage IV breast cancer.
Interventions
- BIOLOGICAL synthetic breast cancer peptides-tetanus toxoid-Montanide ISA-51 vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2005-12 |
| Est. Completion | 2008-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00304096
The ClinicalTrials.gov registry entry for NCT00304096 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Virginia, which has 449 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which synthetic breast cancer peptides-tetanus toxoid-Montanide ISA-51 vaccine is the first listed.
NCT00304096 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00304096 about?
NCT00304096 is a clinical study titled "Vaccine Therapy in Treating Patients With Stage III or Stage IV Breast Cancer". RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Giving booster vaccinations may make a stronger immune response and kill more tumor cells. PURPOSE: This phase I trial is studying the side effects of vaccine therapy in treating patient...
What is the current status of trial NCT00304096?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2005-12. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00304096?
The interventions under investigation include: synthetic breast cancer peptides-tetanus toxoid-Montanide ISA-51 vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00304096?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.